‹< Fetzima’s Pharmacology |
|US brand name: Fetzima|
| Generic name: levomilnacipran extended-release |
This page really isn’t ready yet. As I’ve been updating pages on antidepressants I linked to it just to get that out of the way. And people are finding it via the site search engine, Google, or whatever.
Name, Address, Serial Number (Generic and Overseas Availability)
Available in the US as a generic? No
Shapes & Sizes (How Supplied)
Fetzima comes in capsules imprinted with FL and the dosage in black. Dosages and colors are:
- 20 mg yellow and white capsule
- 40 mg yellow capsule
- 80 mg pink and white capsule
- 120 mg pink capsule
Other Trade Names and Overseas Availability
Not including controlled/extended/sustained release suffixes (Efexor ER, Trevilor retard e.g.) or branded generics that are a hyphenate of the generic name and the drug company name (Apo-Citalopram e.g.).
Full US PI sheet, Global SPCs & PILs, Other Consumer Review & Rating Sites, and Other Sites that may be of Interest
Fetzima’s Full US Prescribing Information / PI Sheet
Other Sites of Interest
If you have any questions not answered here, please see the Crazymeds Fetzima discussion board.
- Fetzima full US Prescribing Information
- Gommoll, Carl P., William M. Greenberg, and Changzheng Chen. “A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.” Journal of Drug Assessment 3.0 (2014): 10-19.
- Bakish, David, Anjana Bose, Carl Gommoll, Changzheng Chen, Rene Nunez, William M. Greenberg, Michael Liebowitz, and Arif Khan. “Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.” Journal of Psychiatry & Neuroscience: JPN 39, no. 1 (2014): 40.
- Shiovitz, Thomas, William M. Greenberg, Changzheng Chen, Giovanna Forero, and Carl P. Gommoll. “A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.” Innovations in Clinical Neuroscience 11, no. 1-2 (2014): 10.
- Blum, Steven I., Stavros Tourkodimitris, and Adam Ruth. “Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.” Journal of Affective Disorders (2014).
- Mago, Rajnish, Giovanna Forero, William M. Greenberg, Carl Gommoll, and Changzheng Chen. “Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study” Clinical Drug Investigation 2013; 33(10): 761–771. Published online 03 September, 2013
- Carrothers, Timothy J., Tatiana Khariton, C. Chen, Antonia Periclou, Laishun Chen, Michelle Green, Leon Bax, Helen Kastrissios, and Parviz Ghahramani. “Population pharmacokinetic model for levomilnacipran in healthy subjects and patients with major depressive disorder.” In American Conference on Pharmacometrics, pp. 12-15. 2013.
‹< Fetzima’s Pharmacology |
Pages and Forum Topics Google Thinks are Relevant to Your Mental Health
||Keep Crazymeds on the air.
Donate some spare electronic currency
you have floating around The Cloud
1 At least links to all the ones with free full-text. Which are about half of those available for Savella. And nothing when compared with the all-except-one count for Brintellix. Hiding anything Forest? Not really. I was lucky to find one or two clinical trials for most other meds. And the one about long-term use being a statistical deadheat was available.
|Last modified on Wed, 04 May, 2016 at 17:16:50 by JerodPoore||Page Author Jerod Poore||Date created Wed, 08 Oct, 2014|
|“Fetzima (levomilnacipran extended-release): Availability, Comments, Links, More” by Jerod Poore is copyright © 2014 Jerod Poore ||Published online 2014/10/08|
Fetzima, and all other drug names on this page and used throughout the site, are the trademarks of someone else. Fetzima’s PI Sheet will probably have the name of the manufacturer and trademark owner (they’re not always the same company) at or near the very bottom. Or ask Google who the owner is. The way pharmaceutical companies buy each other and swap products like Monopoly™ real estate, the ownership of the trademark may have changed without my noticing. It may of changed hands by the time you finished reading this article.
Page design and explanatory material by Jerod Poore, copyright © 2003 - 2016. All rights reserved. See the full copyright notice for full copyright details.
Don’t automatically believe everything you read on teh Intergoogles. No warranty is expressed or implied in this information. Consult one or more doctors and/or pharmacists before taking, or changing how you take any neurological and/or psychiatric medication. Your mileage may vary. What happened to us won’t necessarily happen to you. For more details see the Crazymeds big-ass disclaimer.
Enable Crazymeds’ Financial Solvency!
Enable Crazymeds to keep spreading our knowledge. Donate some spare e-currency you have floating around The Cloud.
Improve Your Social Media Skills
Sites That Probably Suck Less Than Crazymeds
Community, Info & Support